Compare Duolingo Inc (DUOL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs ResMed Inc. — how do they compare? Duolingo Inc trades at $149.92 (market cap $7.08B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 4.5× Duolingo Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and ResMed Inc. for 51 Days on average.
| DUOL | RMD | |
|---|---|---|
Market Cap | $7.08B | $31.89B |
Volume | 729,171 | 618,314 |
Sector | Technology | Health |
52-Week High | $341.08 | $275.96 |
52-Week Low | $90.03 | $182.82 |
Typical Hold Time | 137 Days | 51 Days |
Enterprise Value | $5.85B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $151.22, down 0.33% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue reaching $1.04 billion and net income of $414.07 million, representing a 35.87% net margin. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 surpassing the $0.604 estimate. Technical analysis shows support at $150 and resistance at $152, with the stock trading near recent highs.
Duolingo presents a compelling growth story with strong profitability metrics and consistent earnings beats, though valuation multiples remain elevated. Key risks include insider selling activity and competitive pressures in the edtech space. Analyst consensus leans cautious with 54% hold ratings, but the company's AI-driven content creation and user growth strategy provides long-term upside potential if monetization improves.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
